| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/HYPERTENSIONAHA.112.195115 |
| P698 | PubMed publication ID | 22868389 |
| P50 | author | Xiao Yu Tian | Q42257261 |
| Yu Huang | Q56528909 | ||
| Wing Tak Wong | Q56988879 | ||
| Xiaoqiang Yao | Q57009857 | ||
| Chi-Fai Ng | Q57559727 | ||
| Yi-Xiang Wang | Q61481749 | ||
| P2093 | author name string | Jian Liu | |
| Aimin Xu | |||
| Gang Xu | |||
| Chi Wai Lau | |||
| Karen S L Lam | |||
| Zhiming Zhu | |||
| Zhen Yu Chen | |||
| Limei Liu | |||
| Yunfei Pu | |||
| P2860 | cites work | Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species | Q44987425 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | endothelium | Q111140 |
| hypertension | Q95566669 | ||
| P304 | page(s) | 833-841 | |
| P577 | publication date | 2012-08-06 | |
| P1433 | published in | Hypertension | Q5958695 |
| P1476 | title | Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism | |
| P478 | volume | 60 |
| Q55382850 | A Possible Mechanism: Vildagliptin Prevents Aortic Dysfunction through Paraoxonase and Angiopoietin-Like 3. |
| Q42289875 | A case of "hidden" diabetic nephropathy diagnosed by a combination of renal biopsy findings and continuous glucose monitoring system |
| Q51666275 | A dipeptidyl peptidase-4 inhibitor ameliorates hypertensive cardiac remodeling via angiotensin-II/sodium-proton pump exchanger-1 axis. |
| Q41811427 | Acute hemodynamic and renal effects of glucagon-like peptide 1 analog and dipeptidyl peptidase-4 inhibitor in rats |
| Q33904475 | Additive effects of atorvastatin combined with sitagliptin on rats with myocardial infarction: a pilot study |
| Q35784692 | Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis |
| Q38195527 | Antiatherothrombotic effects of dipeptidyl peptidase inhibitors |
| Q37566950 | Blood pressure control in type 2 diabetic patients |
| Q39870539 | Cardioprotective effects of sitagliptin against doxorubicin-induced cardiotoxicity in rats |
| Q38199984 | Cardiovascular actions of GLP-1 and incretin-based pharmacotherapy. |
| Q38072259 | Cardiovascular effects of gliptins |
| Q64267307 | DPP-4 Inhibitors as Potential Candidates for Antihypertensive Therapy: Improving Vascular Inflammation and Assisting the Action of Traditional Antihypertensive Drugs |
| Q37095161 | DPP-4 Inhibitors as Therapeutic Modulators of Immune Cell Function and Associated Cardiovascular and Renal Insulin Resistance in Obesity and Diabetes |
| Q34109066 | DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study |
| Q43054868 | DPP-4 inhibitor linagliptin ameliorates cardiovascular injury in salt-sensitive hypertensive rats independently of blood glucose and blood pressure |
| Q42007460 | DPP-4 inhibitor sitagliptin prevents inflammation and oxidative stress of heart and kidney in two kidney and one clip (2K1C) rats |
| Q38413395 | DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition. |
| Q54351970 | Di-peptidyl peptidase-4 inhibitor sitagliptin protects vascular function in metabolic syndrome: possible role of epigenetic regulation. |
| Q39103371 | Diabetes, hypertension, and chronic kidney disease progression: role of DPP4. |
| Q36342144 | Dietary salt regulates epithelial sodium channels in rat endothelial cells: adaptation of vasculature to salt |
| Q88778854 | Dipeptidyl peptidase IV (DPP-4) inhibition alleviates pulmonary arterial remodeling in experimental pulmonary hypertension |
| Q38119146 | Dipeptidyl peptidase-4 inhibitors in cardioprotection: a promising therapeutic approach |
| Q38107546 | Dipeptidyl peptidase-4 inhibitors: multitarget drugs, not only antidiabetes drugs. |
| Q35026385 | Dipeptidyl-peptidase 4 inhibition and the vascular effects of glucagon-like peptide-1 and brain natriuretic peptide in the human forearm |
| Q27011819 | Dipeptidyl-peptidase 4 inhibition: linking metabolic control to cardiovascular protection |
| Q38132470 | Direct cardiovascular effects of glucagon like peptide-1. |
| Q38178761 | Do incretins improve endothelial function? |
| Q36448319 | Effect of Dipeptidyl Peptidase-4 Inhibitor on All-Cause Mortality and Coronary Revascularization in Diabetic Patients |
| Q91903639 | Effect of Saxagliptin on Endothelial Function in Patients with Type 2 Diabetes: A Prospective Multicenter Study |
| Q34718326 | Effect of dipeptidyl peptidase 4 inhibition on arterial blood pressure is context dependent |
| Q93185753 | Effect of gemigliptin on cardiac ischemia/reperfusion and spontaneous hypertensive rat models |
| Q38208950 | Effects of GLP-1 in the kidney |
| Q92005722 | Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus |
| Q37232679 | Effects of glucagon-like peptide-1 receptor agonists on renal function |
| Q58566643 | Efficacy of anagliptin as compared to linagliptin on metabolic parameters over 2 years of drug consumption: A retrospective cohort study |
| Q38680112 | Endothelial dysfunction and vascular disease - a 30th anniversary update |
| Q41627358 | Enhanced Mitochondrial Transient Receptor Potential Channel, Canonical Type 3-Mediated Calcium Handling in the Vasculature From Hypertensive Rats |
| Q36438426 | Functional inhibition of urea transporter UT-B enhances endothelial-dependent vasodilatation and lowers blood pressure via L-arginine-endothelial nitric oxide synthase-nitric oxide pathway. |
| Q39204264 | Gastrointestinal Tract: a Promising Target for the Management of Hypertension |
| Q35070635 | Gastrointestinal intervention ameliorates high blood pressure through antagonizing overdrive of the sympathetic nerve in hypertensive patients and rats |
| Q48131140 | Glucagon-like peptide-1 acutely affects renal blood flow and urinary flow rate in spontaneously hypertensive rats despite significantly reduced renal expression of GLP-1 receptors |
| Q33603384 | Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas |
| Q47144545 | Hepatoprotective potential of isoquercitrin against type 2 diabetes-induced hepatic injury in rats |
| Q61451056 | Investigation of a Dipeptidyl Peptidase-4 Inhibitor/Thiazolidinedione Combination Drug for Patients With Type 2 Diabetes and Poor Glycemic Control: Difficulty With Patient Enrollment |
| Q38182499 | Is there a role for the incretin system in blood pressure regulation? |
| Q92815290 | Liraglutide Inhibits Endothelial-to-Mesenchymal Transition and Attenuates Neointima Formation after Endovascular Injury in Streptozotocin-Induced Diabetic Mice |
| Q41480617 | Metformin Improves Endothelial Function and Reduces Blood Pressure in Diabetic Spontaneously Hypertensive Rats Independent from Glycemia Control: Comparison to Vildagliptin |
| Q37707789 | New insights into insulin action and resistance in the vasculature |
| Q38248682 | Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors |
| Q34062829 | Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system |
| Q58565182 | Potentiation of endothelium-dependent vasorelaxation of mesenteric arteries from spontaneously hypertensive rats by gemigliptin, a dipeptidyl peptidase-4 inhibitor class of anti-diabetic drug |
| Q30390165 | Protection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection. |
| Q30415298 | Protein kinase A mediates glucagon-like peptide 1-induced nitric oxide production and muscle microvascular recruitment |
| Q59791110 | Renoprotection Provided by Dipeptidyl Peptidase-4 Inhibitors in Combination with Angiotensin Receptor Blockers in Patients with Type 2 Diabetic Nephropathy |
| Q42876331 | Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes |
| Q46442635 | Rhynchophylline Ameliorates Endothelial Dysfunction via Src-PI3K/Akt-eNOS Cascade in the Cultured Intrarenal Arteries of Spontaneous Hypertensive Rats |
| Q36607551 | Role of growth hormone-releasing hormone in dyslipidemia associated with experimental type 1 diabetes |
| Q48249200 | Significance of circulatory DPP4 activity in metabolic diseases. |
| Q48270894 | Sitagliptin Attenuates Endothelial Dysfunction of Zucker Diabetic Fatty Rats: Implication of the Antiperoxynitrite and Autophagy |
| Q36953818 | Sitagliptin attenuates inflammatory responses in lipopolysaccharide-stimulated cardiomyocytes via nuclear factor-κB pathway inhibition |
| Q37699068 | Substance P increases sympathetic activity during combined angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibition. |
| Q36816043 | TRPV1-mediated UCP2 upregulation ameliorates hyperglycemia-induced endothelial dysfunction |
| Q64990581 | The pathophysiological basis of vascular disease. |
| Q42284707 | The role of endothelial nitric oxide in the anti-restenotic effects of liraglutide in a mouse model of restenosis. |
| Q37617567 | Type 2 diabetes mellitus and hypertension: an update |
| Q34240788 | Uncoupling protein-2 mediates DPP-4 inhibitor-induced restoration of endothelial function in hypertension through reducing oxidative stress |
| Q51615023 | Vascular effects of linagliptin in non-obese diabetic mice are glucose-independent and involve positive modulation of the endothelial nitric oxide synthase (eNOS)/caveolin-1 (CAV-1) pathway. |
| Q38371242 | Vascular protection with dipeptidyl peptidase-IV inhibitors in diabetes: experimental and clinical therapeutics |
Search more.